A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
This is an open-label, multicenter, phase 1 study of BBI608 in combination with Sorafenib. This study population is adult Japanese patients with advanced hepatocellular carcinoma in Sorafenib combination therapy.
Hepatocellular Carcinoma
DRUG: BBI608|DRUG: Sorafenib
Assessment of safety and tolerability of BBI608 given in combination with Sorafenib by reporting of adverse events and serious adverse events., 7 month|Assessment of dose-limiting toxicities (DLTs)., 29 days|Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib., On day 1: Prior to BBI608 dosing and 2,4,6,8,10,12 and 24 hours after the first dose. On day 29: Prior to BBI608 dosing and 2,4,6,8,10,12 and 24 hours after the first dose.
Assessment of the preliminary anti-tumour activity., Anti-tumour activity is assessed every 8 weeks from the first dose of BBI608 after the last dose of BBI608.The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with hepatocellular carcinoma., Approximately 7 months|Progression Free Survival, The time the participant stays on study until progression will be measured and recorded., Approximately 7 month|Overall Survival, Participants follow-up for overall survival will occur. Maximum follow-up time is 1 year after the initial administration of the last subject., Approximately 1 year
This is an open-label, multicenter, phase 1 study of BBI608 in combination with Sorafenib. This study population is adult Japanese patients with advanced hepatocellular carcinoma in Sorafenib combination therapy.